CSPC Baike (Shandong) Biopharmaceutical Co. Ltd. has patented new polycyclic compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of Alzheimer’s disease, obesity, type 2 diabetes and nonalcoholic fatty liver disease (NAFLD; MASLD).